|
1
|
Halsted WS: The results of operations for
the cure of cancer of the breast performed at the Johns Hopkins
Hospital from June, 1889, to January, 1894. Ann Surg. 20:497–555.
1894. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Darby S, McGale P, Correa C, Taylor C,
Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, et
al: Early Breast Cancer Trialists' Collaborative Group (EBCTCG):
Effect of radiotherapy after breast-conserving surgery on 10-year
recurrence and 15-year breast cancer death: Meta-analysis of
individual patient data for 10,801 women in 17 randomised trials.
Lancet. 378:1707–1716. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Veronesi U, Zucali R and Luini A: Local
control and survival in early breast cancer: The Milan trial. Int J
Radiat Oncol Biol Phys. 12:717–720. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ansieau S, Bastid J, Doreau A, Morel AP,
Bouchet BP, Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S,
et al: Induction of EMT by twist proteins as a collateral effect of
tumor-promoting inactivation of premature senescence. Cancer Cell.
14:79–89. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lal I, Dittus K and Holmes CE: Platelets,
coagulation and fibri-nolysis in breast cancer progression. Breast
Cancer Res. 15:2072013. View
Article : Google Scholar
|
|
7
|
Takagi S, Takemoto A, Takami M, Oh-Hara T
and Fujita N: Platelets promote osteosarcoma cell growth through
activation of the platelet-derived growth factor receptor-Akt
signaling axis. Cancer Sci. 105:983–988. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bambace NM and Holmes CE: The platelet
contribution to cancer progression. J Thromb Haemost. 9:237–249.
2011. View Article : Google Scholar
|
|
9
|
Ludwig RJ, Boehme B, Podda M, Henschler R,
Jager E, Tandi C, Boehncke WH, Zollner TM, Kaufmann R and Gille J:
Endothelial P-selectin as a target of heparin action in
experimental melanoma lung metastasis. Cancer Res. 64:2743–2750.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Labelle M, Begum S and Hynes RO: Direct
signaling between platelets and cancer cells induces an
epithelial-mesenchymal-like transition and promotes metastasis.
Cancer Cell. 20:576–590. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang AD, Fan F, Camp ER, van Buren G, Liu
W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic
oxaliplatin resistance induces epithelial-to-mesenchymal transition
in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kajiyama H, Shibata K, Terauchi M,
Yamashita M, Ino K, Nawa A and Kikkawa F: Chemoresistance to
paclitaxel induces epithelial-mesenchymal transition and enhances
metastatic potential for epithelial ovarian carcinoma cells. Int J
Oncol. 31:277–283. 2007.PubMed/NCBI
|
|
13
|
von Minckwitz G, Untch M, Blohmer JU,
Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich
J, Huober J, et al: Definition and impact of pathologic complete
response on prognosis after neoadjuvant chemotherapy in various
intrinsic breast cancer subtypes. J Clin Oncol. 30:1796–1804. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lønning PE and Knappskog S: Mapping
genetic alterations causing chemoresistance in cancer: Identifying
the roads by tracking the drivers. Oncogene. 32:5315–5330. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Castells M, Thibault B, Delord JP and
Couderc B: Implication of tumor microenvironment in
chemoresistance: Tumor-associated stromal cells protect tumor cells
from cell death. Int J Mol Sci. 13:9545–9571. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumours. 7th edition.
Wiley-Blackwell; Hoboken, NJ: 2009
|
|
17
|
Devitee FATP: Pathology and Genetics
Tumours of the Breast and Female Genital Organs. World Health
Organization (WHO) guidelines; 2002
|
|
18
|
Bremer M and Doerge RW: Statistics at the
Bench: A Step-by-Step Handbook for Biologists. Cold Spring Harbor
Laboratory Press; Long Island, NY: 2010
|
|
19
|
Lian L, Li W, Li ZY, Mao YX, Zhang YT,
Zhao YM, Chen K, Duan WM and Tao M: Inhibition of MCF-7 breast
cancer cell-induced platelet aggregation using a combination of
anti-platelet drugs. Oncol Lett. 5:675–680. 2013.PubMed/NCBI
|
|
20
|
Heinmöller E, Weinel RJ, Heidtmann HH,
Salge U, Seitz R, Schmitz I, Müller KM and Zirngibl H: Studies on
tumor-cell-induced platelet aggregation in human lung cancer cell
lines. J Cancer Res Clin Oncol. 122:735–744. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bazou D, Santos-Martinez MJ, Medina C and
Radomski MW: Elucidation of flow-mediated tumour cell-induced
platelet aggregation using an ultrasound standing wave trap. Br J
Pharmacol. 162:1577–1589. 2011. View Article : Google Scholar :
|
|
22
|
Medina C, Jurasz P, Santos-Martinez MJ,
Jeong SS, Mitsky T, Chen R and Radomski MW: Platelet
aggregation-induced by caco-2 cells: Regulation by matrix
metalloproteinase-2 and adenosine diphosphate. J Pharmacol Exp
Ther. 317:739–745. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miyashita T, Tajima H, Makino I,
Nakagawara H, Kitagawa H, Fushida S, Harmon JW and Ohta T:
Metastasis-promoting role of extravasated platelet activation in
tumor. J Surg Res. 193:289–294. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kuznetsov HS, Marsh T, Markens BA, Castaño
Z, Greene-Colozzi A, Hay SA, Brown VE, Richardson AL, Signoretti S,
Battinelli EM, et al: Identification of luminal breast cancers that
establish a tumor-supportive macroenvironment defined by
proangiogenic platelets and bone marrow-derived cells. Cancer
Discov. 2:1150–1165. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Devarajan E, Song YH, Krishnappa S and Alt
E: Epithelial- mesenchymal transition in breast cancer lines is
mediated through PDGF-D released by tissue-resident stem cells. Int
J Cancer. 131:1023–1031. 2012. View Article : Google Scholar
|
|
26
|
Eger A, Stockinger A, Park J, Langkopf E,
Mikula M, Gotzmann J, Mikulits W, Beug H and Foisner R:
Beta-catenin and TGFbeta signalling cooperate to maintain a
mesenchymal phenotype after FosER-induced epithelial to mesenchymal
transition. Oncogene. 23:2672–2680. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Radziwon-Balicka A, Medina C, O'Driscoll
L, Treumann A, Bazou D, Inkielewicz-Stepniak I, Radomski A, Jow H
and Radomski MW: Platelets increase survival of adenocarcinoma
cells challenged with anticancer drugs: Mechanisms and implications
for chemoresistance. Br J Pharmacol. 167:787–804. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sayan AE: Tumour-promoting role of
EMT-inducing transcription factor ZEB1 in mantle cell lymphoma.
Cell Death Differ. 21:194–195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fang H, Placencio VR and DeClerck YA:
Protumorigenic activity of plasminogen activator inhibitor-1
through an antiapoptotic function. J Natl Cancer Inst.
104:1470–1484. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kopp HG, Placke T and Salih HR:
Platelet-derived transforming growth factor-beta down-regulates
NKG2D thereby inhibiting natural killer cell antitumor reactivity.
Cancer Res. 69:7775–7783. 2009. View Article : Google Scholar : PubMed/NCBI
|
